COVID-19

Viral and Symptom Rebound in Untreated COVID-19 Infection | Cognitive Impairment 13 Months After Hospitalization for COVID-19 | Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld©) for COVID-19 among 1112 severely immunocompromised patients | Extended Remdesivir Infusion for Persistent COVID-19 Infection | Association between AZD7442 (tixagevimab-cilgavimab) administration and SARS-CoV-2 infection, hospitalization and mortality | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label, platform trial and updated meta-analysis

Children and COVID-19: State level Data Report | SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses | Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages | CDC Recommends Novavax’s COVID-19 Vaccine for Adults | Paxlovid in patients who are immunocompromised and hospitalized with SARS-CoV-2 infection | Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

Neurovascular injury with complement activation and inflammation in COVID-19 | Factors Associated with Severe Outcomes Among Immunocompromised Adults Hospitalized for COVID-19 — COVID-NET, 10 States, March 2020–February 2022 | Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, & BA.5 | Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants | Parental COVID-19 Vaccine Hesitancy in Diverse Communities: A National Survey | Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis | Rapid Diagnostic Testing for Response to the Monkeypox Outbreak — Laboratory Response Network, United States, May 17–June 30, 2022

Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation | Health Impairments in Children and Adolescents After Hospitalization for Acute COVID-19 or MIS-C | Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection | Children and COVID-19: State level Data Report | COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022 | Comparative Effectiveness of the SARS-CoV-2 Vaccines During Delta | In adults hospitalized with COVID-19, high- vs low-dose venous thromboprophylaxis reduces venous thromboembolism but increases major bleeding

Children and COVID-19: State level Data Report | Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomized, open label, superiority trial | Pediatric SARS-CoV-2 Seroprevalence in Arkansas Over the First Year of the COVID-19 Pandemic and Antibody Responses to SARS-CoV-2 in Children With COVID-19 | All-Cause Maternal Mortality in the US Before vs During the COVID-19 Pandemic

Outcomes of SARS-CoV-2 Reinfection | Children and COVID-19: State level Data Report | CDC Recommends COVID-19 Vaccines for Young Children | Evaluating clinical effectiveness of SARS-CoV-2 vaccine in solid organ transplant recipients: A propensity score matched analysis | Therapeutic efficacy of monoclonal antibodies and antivirals against SARS-CoV-2 Omicron BA.1 in Syrian hamsters | Rebound Phenomenon after Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease-2019 in High-Risk Persons | Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment — California, December 2021–May 2022

Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial | Persistence of residual SARS-CoV-2 viral antigen and RNA in tissues of patients with long COVID-19 | Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19 | Rebound Phenomenon after Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease-2019 in High-Risk Persons | The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination